© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Vascular endothelial growth factor-D expression in human atherosclerotic lesions
aDepartment of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland
bDepartment of Cardiovascular Surgery, University of Kuopio, Kuopio, Finland
cProvincial State Office of Eastern Finland, Kuopio, Finland
dLudwig Institute for Cancer Research, Post Office Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
eMolecular/Cancer Biology Laboratory, Biomedicum, University of Helsinki, Helsinki, Finland
fDepartment of Medicine, University of Kuopio, Kuopio, Finland
gGene Therapy Unit, Kuopio University Hospital, Kuopio, Finland
seppo.ylaherttuala{at}uku.fi
* Corresponding author. Tel.: +358-17-162-075; fax: +358-17-163-751.
Objective: Vascular endothelial growth factor-D (VEGF-D) is a recently characterized member of the VEGF family, but its expression in atherosclerotic lesions remains unknown. We studied the expression of VEGF-D and its receptors (VEGFR-2 and VEGFR-3) in normal and atherosclerotic human arteries, and compared that to the expression pattern of VEGF-A. Methods: Human arterial samples (n=39) obtained from amputation operations and fast autopsies were classified according to the stage of atherosclerosis and studied by immunohistochemistry. The results were confirmed by in situ hybridization and RT-PCR. Results: We found that while VEGF-A expression increased during atherogenesis, VEGF-D expression remained relatively stable only decreasing in complicated lesions. In normal arteries and in early lesions VEGF-D was mainly expressed in smooth muscle cells, whereas in complicated atherosclerotic lesions the expression was most prominent in macrophages and also colocalized with plaque neovascularization. By comparing the staining profiles of different antibodies, we found that proteolytic processing of VEGF-D was efficient in the vessel wall. VEGFR-2, but not VEGFR-3, was expressed in the vessel wall at every stage of atherosclerosis. Conclusions: Our results suggest that in large arteries VEGF-D is mainly expressed in smooth muscle cells and that it may have a role in the maintenance of vascular homeostasis. However, in complicated lesions it was also expressed in macrophages and may contribute to plaque neovascularization. The constitutive expression of VEGFR-2 in arteries suggests that it may be one of the principal mediators of the VEGF-D effects in large arteries.
KEYWORDS Arteries; Atherosclerosis; Gene expression; Growth
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K Kinnunen, T Puustjarvi, M Terasvirta, P Nurmenniemi, T Heikura, S Laidinen, T Paavonen, H Uusitalo, and S Yla-Herttuala Differences in retinal neovascular tissue and vitreous humour in patients with type 1 and type 2 diabetes Br J Ophthalmol, August 1, 2009; 93(8): 1109 - 1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. I. Toivanen, T. Nieminen, L. Viitanen, A. Alitalo, M. Roschier, S. Jauhiainen, J. E. Markkanen, O. H. Laitinen, T. T. Airenne, T. A. Salminen, et al. Novel Vascular Endothelial Growth Factor D Variants with Increased Biological Activity J. Biol. Chem., June 5, 2009; 284(23): 16037 - 16048. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Birk, J. Barbato, L. Mureebe, and R. A. Chaer Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation Vascular and Endovascular Surgery, January 1, 2009; 42(6): 517 - 530. [Abstract] [PDF] |
||||
![]() |
V. Tchaikovski, G. Fellbrich, and J. Waltenberger The Molecular Basis of VEGFR-1 Signal Transduction Pathways in Primary Human Monocytes Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 322 - 328. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kivela, M. Silvennoinen, M. Lehti, H. Kainulainen, and V. Vihko Effects of acute exercise, exercise training, and diabetes on the expression of lymphangiogenic growth factors and lymphatic vessels in skeletal muscle Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2573 - H2579. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yla-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen Vascular Endothelial Growth Factors: Biology and Current Status of Clinical Applications in Cardiovascular Medicine J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1015 - 1026. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Roy, S. Bhardwaj, M. Babu, I. Kokina, S. Uotila, T. Ahtialansaari, T. Laitinen, J. Hakumaki, M. Laakso, K.-H. Herzig, et al. VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-{kappa}B, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits FASEB J, October 1, 2006; 20(12): 2159 - 2161. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Herrmann, L. O. Lerman, D. Mukhopadhyay, C. Napoli, and A. Lerman Angiogenesis in Atherogenesis Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 1948 - 1957. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schmeisser, M. Christoph, A. Augstein, R. Marquetant, M. Kasper, R.C. Braun-Dullaeus, and R.H. Strasser Apoptosis of human macrophages by Flt-4 signaling: Implications for atherosclerotic plaque pathology Cardiovasc Res, September 1, 2006; 71(4): 774 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-H. Ueng, C.-C. Hung, M.-L. Kuo, P.-K. Chan, S.-H. Hu, P.-C. Yang, and L. W. Chang Induction of Fibroblast Growth Factor-9 and Interleukin-1{alpha} Gene Expression by Motorcycle Exhaust Particulate Extracts and Benzo(a)pyrene in Human Lung Adenocarcinoma Cells Toxicol. Sci., October 1, 2005; 87(2): 483 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Leppanen, S. Koota, I. Kholova, J. Koponen, C. Fieber, U. Eriksson, K. Alitalo, and S. Yla-Herttuala Gene Transfers of Vascular Endothelial Growth Factor-A, Vascular Endothelial Growth Factor-B, Vascular Endothelial Growth Factor-C, and Vascular Endothelial Growth Factor-D Have No Effects on Atherosclerosis in Hypercholesterolemic Low-Density Lipoprotein-Receptor/Apolipoprotein B48-Deficient Mice Circulation, August 30, 2005; 112(9): 1347 - 1352. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. Chang, G. Garcia-Cardena, F. Farnebo, M. Fannon, E. J. Chen, C. Butterfield, M. A. Moses, R. C. Mulligan, J. Folkman, and A. Kaipainen Dose-dependent response of FGF-2 for lymphangiogenesis PNAS, August 10, 2004; 101(32): 11658 - 11663. [Abstract] [Full Text] [PDF] |
||||










